Renalytix Plc develops AI-enabled in vitro diagnostic solutions for kidney diseases. Its KidneyIntelX platform employs an algorithm that assesses various patient data inputs, including genetics, biomarkers and electronic health records, to generate a patient risk score. Renalytix AI plc has several collaborations to develop and commercialize AI-powered diagnostic products for kidney disease and antibody detection for SARS-CoV-2.